TG100713 (also known as TG-100713) is a small molecule drug developed by the pharmaceutical company Tragara Pharmaceuticals. It is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a class of enzymes that play a critical role in the regulation of cell growth and survival. TG100713 is currently being studied as a potential treatment for various types of cancer.
Chemical name: The chemical name of TG100713 is N-(4-((2-(diethylamino)ethyl)amino)-2-methylphenyl)-3-(5-fluoro-2-((3-(trifluoromethyl)phenyl)amino)pyridin-3-yl)propanamide.
Molecular formula: The molecular formula for TG100713 is C29H34F4N4O2.
Formula weight: The formula weight for TG100713 is 564.6 g/mol.
CAS No: The CAS number for TG100713 is 925705-73-3.
Top Ten Keywords and Synonyms:
Synonyms: TG-100713; TG 100713; N-(4-((2-(diethylamino)ethyl)amino)-2-methylphenyl)-3-(5-fluoro-2-((3-(trifluoromethyl)phenyl)amino)pyridin-3-yl)propanamide
Health Benefits of TG100713: TG100713 is designed to inhibit the activity of PI3K, which is known to be overactive in many types of cancer cells. By inhibiting PI3K, TG100713 may help to slow or stop the growth of cancer cells, potentially leading to tumor regression and improved patient outcomes.
Potential Effects of TG100713: Preclinical studies have shown that TG100713 can inhibit the growth of various types of cancer cells, including breast, lung, and ovarian cancer cells. Additionally, TG100713 has been shown to induce apoptosis (cell death) and autophagy (a process by which cells degrade and recycle their own components) in cancer cells.
Product Mechanism: TG100713 works by targeting and inhibiting the activity of PI3K, an enzyme that plays a key role in the regulation of cell growth and survival. The inhibition of PI3K by TG100713 leads to reduced activation of downstream signaling pathways, including the AKT pathway, which is known to promote cell growth and survival. This results in decreased cancer cell proliferation and increased sensitivity to chemotherapy and radiation therapy.
Safety: As with any new drug, the safety of TG100713 is being carefully evaluated in clinical trials. Preliminary studies suggest that TG100713 is generally well-tolerated, with manageable side effects.
Side Effects: Common side effects of TG100713 include fatigue, nausea, vomiting, and diarrhea. Less common but more serious side effects may include low white blood cell count, liver damage, and heart problems.
Dosing Information: The appropriate dose of TG100713 depends on several factors, including the patient's age, weight, and overall health status. Dosage and duration of treatment are determined by the treating physician.
Conclusion: TG100713 is a promising new drug under investigation for the treatment of various types of cancer. By inhibiting the activity of PI3K, it has the potential to slow or stop the growth of tumors, potentially improving patient outcomes. While the drug is still in clinical trials, preliminary studies suggest that it is generally well-tolerated with manageable side effects. As research continues, TG100713 may represent an exciting new option for patients with cancer